Roche’s US subsidiary Genentech announces manufacturing expansion in the United States

Summary

Genentech announced a $750 million investment in a new device fill-finish manufacturing facility at its Hillsboro, Oregon campus to expand capacity for future pipeline medicines. The expansion will add end-to-end device filling capabilities to support Roche and Genentech's innovative medicine portfolio.